Compare Mesoblast Limited (MESO) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Short Term Corporate Bond ETF — how do they compare? Mesoblast Limited trades at $16.96 (market cap $2.21B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Mesoblast Limited is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| MESO | VCSH | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Fixed Income |
52-Week High | $20.96 | $80.20 |
52-Week Low | $12.88 | $78.41 |
Enterprise Value | $2.21B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
